Next Article in Journal
The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature
Next Article in Special Issue
Mutated Measles Virus Matrix and Fusion Protein Influence Viral Titer In Vitro and Neuro-Invasion in Lewis Rat Brain Slice Cultures
Previous Article in Journal
The 20th Anniversary Meeting of the Rocky Mountain Virology Association
 
 
Article

Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids

1
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 65 Stockholm, Sweden
2
National Veterinary Institute, 756 51 Uppsala, Sweden
3
Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
4
Unit of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute and Karolinska University Hospital, 171 77 Stockholm, Sweden
*
Author to whom correspondence should be addressed.
Authors contributed equally.
Academic Editors: Akio Adachi and Masako Nomaguchi
Viruses 2021, 13(1), 37; https://doi.org/10.3390/v13010037
Received: 26 November 2020 / Revised: 22 December 2020 / Accepted: 24 December 2020 / Published: 29 December 2020
RNA viruses have gained plenty of attention during recent outbreaks of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika virus (ZIKV), and Ebola virus. ZIKV is a vector borne Flavivirus that is spread by mosquitoes and it mainly infects neuronal progenitor cells. One hallmark of congenital ZIKV disease is a reduced brain size in fetuses, leading to severe neurological defects. The World Health Organization (WHO) is urging the development of new antiviral treatments against ZIKV, as there are no efficient countermeasures against ZIKV disease. Previously, we presented a new class of host-targeting antivirals active against a number of pathogenic RNA viruses, such as SARS-CoV-2. Here, we show the transfer of the image-based phenotypic antiviral assay to ZIKV-infected brain cells, followed by mechanism-of-action studies and a proof-of-concept study in a three-dimensional (3D) organoid model. The novel antiviral compounds showed a therapeutic window against ZIKV in several cell models and rescued ZIKV-induced neurotoxicity in brain organoids. The compound’s mechanism-of-action was pinpointed to late steps in the virus life cycle, impairing the formation of new virus particles. Collectively, in this study, we expand the antiviral activity of new small molecule inhibitors to a new virus class of Flaviviruses, but also uncover compounds’ mechanism of action, which are important for the further development of antivirals. View Full-Text
Keywords: Zika virus; pathogenic RNA viruses; antivirals; brain organoids; mode-of-action Zika virus; pathogenic RNA viruses; antivirals; brain organoids; mode-of-action
Show Figures

Figure 1

MDPI and ACS Style

Pettke, A.; Tampere, M.; Pronk, R.; Wallner, O.; Falk, A.; Warpman Berglund, U.; Helleday, T.; Mirazimi, A.; Puumalainen, M.-R. Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids. Viruses 2021, 13, 37. https://doi.org/10.3390/v13010037

AMA Style

Pettke A, Tampere M, Pronk R, Wallner O, Falk A, Warpman Berglund U, Helleday T, Mirazimi A, Puumalainen M-R. Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids. Viruses. 2021; 13(1):37. https://doi.org/10.3390/v13010037

Chicago/Turabian Style

Pettke, Aleksandra, Marianna Tampere, Robin Pronk, Olov Wallner, Anna Falk, Ulrika Warpman Berglund, Thomas Helleday, Ali Mirazimi, and Marjo-Riitta Puumalainen. 2021. "Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids" Viruses 13, no. 1: 37. https://doi.org/10.3390/v13010037

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop